Blueprint Medicines: A New Twist On Kinase Discovery
This article was originally published in Start Up
Executive Summary
The convergence of maturing technology, growing industry demand for combination therapy, and regulatory innovation have given rise to Blueprint Medicines, a pure-play kinase specialist that aspires to become a US-focused cancer company.